Risk of Reactivation of Latent HBV Hepatitis in Patients Under Neurosurgical Treatment | OMICS International | Abstract
E-ISSN: 2314-7326
P-ISSN: 2314-7334

Journal of Neuroinfectious Diseases
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Short Communication

Risk of Reactivation of Latent HBV Hepatitis in Patients Under Neurosurgical Treatment

Yoshikazu Ogawa1* and Teiji Tominaga2

1Department of Neurosurgery, Kohnan Hospital, Japan

2Departments of Pathology and Neurosurgery, Tohoku University Graduate School of Medicine, Japan

*Corresponding Author:
Yoshikazu Ogawa
Departments of Pathology and Neurosurgery
Tohoku University Graduate School of Medicine
1-1 Seiryo-machi, Aoba-ku, Sendai
Miyagi 980-8574, Japan
Tel: +81222482131
Fax: +81223041641
E-mail: [email protected]

Received date: Oct 04, 2016; Accepted date: Oct 18, 2016; Published date: Oct 20, 2016

Citation: Ogawa Y, Tominaga T (2016) Risk of Reactivation of Latent HBV Hepatitis in Patients Under Neurosurgical Treatment . J Neuroinfect Dis 7:230. doi:10.4172/2314-7326.1000230

Copyright: © 2016 Ogawa Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Reactivation of hepatitis B virus (HBV) is a risk in the 350 million HBV carriers worldwide. HBV reactivation may cause hepatocellular carcinoma, cirrhosis, and fulminant hepatitis, and HBV reactivation accompanied with malignant tumor and/or chemotherapy is a critical problem for the patients with chronic HBV infection. In addition, multiple risk factors causing immunosuppressive state can also induce HBV reactivation, which includes a few cases of intrinsic cortisol over secretion as Cushing’s syndrome or very low-dose steroid treatment for hypopituitarism after pituitary surgeries.

Appropriate screening methods and the discussion for preventive supplementation of antiviral drugs for HBV reactivation are required. For patients with pituitary tumors precise operative procedures and careful treatment planning are essentially required to avoid HBV reactivation.